Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 25

1.

Prevalence of Carnitine Deficiency and Decreased Carnitine Levels in Patients on Peritoneal Dialysis.

Shimizu S, Takashima H, Tei R, Furukawa T, Okamura M, Kitai M, Nagura C, Maruyama T, Higuchi T, Abe M.

Nutrients. 2019 Nov 4;11(11). pii: E2645. doi: 10.3390/nu11112645.

2.

Correlation between Aortic Calcification Score and Biochemical Parameters in Hemodialysis Patients.

Maruyama N, Higuchi T, Ono M, Oguma H, Nakamura Y, Utsunomiya K, Akiya Y, Horikami T, Yamazaki T, Okawa E, Ando H, Abe M.

Contrib Nephrol. 2019;198:40-51. doi: 10.1159/000496717. Epub 2019 Apr 16.

PMID:
30991412
3.

Prevalence of Carnitine Deficiency and Decreased Carnitine Levels in Patients on Hemodialysis.

Hatanaka Y, Higuchi T, Akiya Y, Horikami T, Tei R, Furukawa T, Takashima H, Tomita H, Abe M.

Blood Purif. 2019;47 Suppl 2:38-44. doi: 10.1159/000496720. Epub 2019 Apr 3.

PMID:
30943487
4.

Efficacy of L-carnitine supplementation for improving lean body mass and physical function in patients on hemodialysis: a randomized controlled trial.

Maruyama T, Maruyama N, Higuchi T, Nagura C, Takashima H, Kitai M, Utsunomiya K, Tei R, Furukawa T, Yamazaki T, Okawa E, Ando H, Kikuchi F, Abe M.

Eur J Clin Nutr. 2019 Feb;73(2):293-301. doi: 10.1038/s41430-018-0348-y. Epub 2018 Oct 23.

PMID:
30353121
5.

Effects of Levocarnitine on Cardiac Function and Renal Anemia in Hemodialysis Patients.

Higuchi T.

Contrib Nephrol. 2018;196:96-100. doi: 10.1159/000485706. Epub 2018 Jul 24. Review.

PMID:
30041211
6.

Levocarnitine Injections Decrease the Need for Erythropoiesis-Stimulating Agents in Hemodialysis Patients with Renal Anemia.

Maruyama T, Higuchi T, Yamazaki T, Okawa E, Ando H, Oikawa O, Inoshita A, Okada K, Abe M.

Cardiorenal Med. 2017 Jun;7(3):188-197. doi: 10.1159/000462983. Epub 2017 Apr 20.

7.

Efficacy and Safety of Pregabalin for the Treatment of Neuropathic Pain in Patients Undergoing Hemodialysis.

Otsuki T, Higuchi T, Yamazaki T, Okawa E, Okada K, Abe M.

Clin Drug Investig. 2017 Jan;37(1):95-102. doi: 10.1007/s40261-016-0464-1.

PMID:
27660209
8.

Efficacy and safety of saxagliptin, a dipeptidyl peptidase-4 inhibitor, in hemodialysis patients with diabetic nephropathy: A randomized open-label prospective trial.

Abe M, Higuchi T, Moriuchi M, Okamura M, Tei R, Nagura C, Takashima H, Kikuchi F, Tomita H, Okada K.

Diabetes Res Clin Pract. 2016 Jun;116:244-52. doi: 10.1016/j.diabres.2016.04.034. Epub 2016 Apr 26.

9.

Levocarnitine Improves Cardiac Function in Hemodialysis Patients With Left Ventricular Hypertrophy: A Randomized Controlled Trial.

Higuchi T, Abe M, Yamazaki T, Okawa E, Ando H, Hotta S, Oikawa O, Kikuchi F, Okada K, Soma M.

Am J Kidney Dis. 2016 Feb;67(2):260-70. doi: 10.1053/j.ajkd.2015.09.010. Epub 2015 Oct 23.

PMID:
26508680
10.

Association of restless legs syndrome with oxidative stress and inflammation in patients undergoing hemodialysis.

Higuchi T, Abe M, Mizuno M, Yamazaki T, Suzuki H, Moriuchi M, Oikawa O, Okawa E, Ando H, Okada K.

Sleep Med. 2015 Aug;16(8):941-8. doi: 10.1016/j.sleep.2015.03.025. Epub 2015 May 8.

PMID:
26070856
11.

Oral zinc supplementation reduces the erythropoietin responsiveness index in patients on hemodialysis.

Kobayashi H, Abe M, Okada K, Tei R, Maruyama N, Kikuchi F, Higuchi T, Soma M.

Nutrients. 2015 May 15;7(5):3783-95. doi: 10.3390/nu7053783.

12.

Effects of levocarnitine on brachial-ankle pulse wave velocity in hemodialysis patients: a randomized controlled trial.

Higuchi T, Abe M, Yamazaki T, Mizuno M, Okawa E, Ando H, Oikawa O, Okada K, Kikuchi F, Soma M.

Nutrients. 2014 Dec 22;6(12):5992-6004. doi: 10.3390/nu6125992.

13.

The dipeptidyl peptidase-4 inhibitor alogliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis.

Fujii Y, Abe M, Higuchi T, Mizuno M, Suzuki H, Matsumoto S, Ito M, Maruyama N, Okada K, Soma M.

Expert Opin Pharmacother. 2013 Feb;14(3):259-67. doi: 10.1517/14656566.2013.761690. Epub 2013 Jan 7.

PMID:
23289982
14.

The dipeptidyl peptidase-4 (DPP-4) inhibitor vildagliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis.

Ito M, Abe M, Okada K, Sasaki H, Maruyama N, Tsuchida M, Higuchi T, Kikuchi F, Soma M.

Endocr J. 2011;58(11):979-87. Epub 2011 Sep 15.

15.

Zinc-finger transcriptional factor Sall1 induces angiogenesis by activation of the gene for VEGF-A.

Yamamoto C, Fukuda N, Matsumoto T, Higuchi T, Ueno T, Matsumoto K.

Hypertens Res. 2010 Feb;33(2):143-8. doi: 10.1038/hr.2009.195. Epub 2009 Nov 27.

PMID:
19942929
16.

Evaluation of serum fetuin-A relationships with biochemical parameters in patients on hemodialysis.

Oikawa O, Higuchi T, Yamazaki T, Yamamoto C, Fukuda N, Matsumoto K.

Clin Exp Nephrol. 2007 Dec;11(4):304-308. doi: 10.1007/s10157-007-0499-y. Epub 2007 Dec 21.

PMID:
18085392
17.

A case report of hemodialysis intolerance with eosinophilia.

Higuchi T, Yamazaki T, Ohnishi Y, Matsumoto S, Yabuki M, Kitajima S, Toshida Y, Maruyama N, Oikawa O, Okada K, Fukuda N, Soma M, Matsumoto K.

Ther Apher Dial. 2007 Feb;11(1):70-3.

PMID:
17309578
18.

Correction of copper deficiency improves erythropoietin unresponsiveness in hemodialysis patients with anemia.

Higuchi T, Matsukawa Y, Okada K, Oikawa O, Yamazaki T, Ohnishi Y, Fujita T, Fukuda N, Soma M, Matsumoto K.

Intern Med. 2006;45(5):271-3. Epub 2006 Apr 3.

19.

The influence of uremic serum on interleukin-1beta and interleukin-1 receptor antagonist production by peripheral blood mononuclear cells.

Higuchi T, Fukuda N, Yamamoto C, Yamazaki T, Oikawa O, Ohnishi Y, Okada K, Soma M, Matsumoto K.

Ther Apher Dial. 2006 Feb;10(1):65-71.

PMID:
16556139
20.

Prolonged protective effect of short daily hemodialysis against dialysis-induced hypotension.

Okada K, Abe M, Hagi C, Maruyama T, Maruyama N, Ito K, Higuchi T, Matsumoto K, Takahashi S.

Kidney Blood Press Res. 2005;28(2):68-76. Epub 2005 Jan 25.

Supplemental Content

Loading ...
Support Center